Skip to main content
SpringerLink
Log in

Quality of Life as an Outcome and a Mediator of Other Outcomes in Patients with Schizophrenia

  • Chapter
  • First Online:
Beyond Assessment of Quality of Life in Schizophrenia

  • 955 Accesses

Abstract

During the past decades subjective quality of life (hereafter QOL) has been proven to be a valid and useful outcome criterion in patients with schizophrenia besides the assessment of clinical parameters such as symptoms or daily functioning. Important predictors for a favorable outcome in patients with schizophrenia are a shorter duration of untreated psychosis, better premorbid functioning, an early treatment response, a lower level of psychopathology or illness severity, and better daily and social functioning at beginning of treatment (Lambert et al. 2010a). Clinical outcome is further compromised by a high risk of medication nonadherence and service disengagement (Velligan et al. 2009) and of comorbid disorders, especially substance use (Fleischhacker et al. 2008). All these factors directly or indirectly mediate QOL in patients with schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11:95–106.

    Article  PubMed  Google Scholar 

  • Acta. http://www.actassociation.org. Brighton; 2001–2012.

  • Addington DE, McKenzie E, Wang J. Validity of hospital admission as an outcome measure of services for first-episode psychosis. Psychiatr Serv (Washington, DC). 2012;63:280–2.

    Article  Google Scholar 

  • AlAqeel B, Margolese HC. Remission in schizophrenia: critical and systematic review. Harv Rev Psychiatry. 2012;20:281–97.

    Article  PubMed  Google Scholar 

  • Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009;12:536–43.

    Article  PubMed  Google Scholar 

  • Amador XF, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873–9.

    Article  CAS  PubMed  Google Scholar 

  • Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51:826–36.

    Article  CAS  PubMed  Google Scholar 

  • Andreasen NC, Carpenter Jr WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–9.

    Article  PubMed  Google Scholar 

  • Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2012;30:183–95.

    Article  PubMed  Google Scholar 

  • Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27:625–36.

    Article  PubMed  Google Scholar 

  • Barnes TR, Drake RJ, Dunn G, et al. Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. Br J Psychiatry. 2013;203:215–20.

    Article  PubMed  Google Scholar 

  • Bechdolf A, Pukrop R, Kohn D, et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res. 2005;79:137–43.

    Article  PubMed  Google Scholar 

  • Bobes J, Ciudad A, Alvarez E, et al. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009;115:58–66.

    Article  PubMed  Google Scholar 

  • Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107:232–7.

    Article  PubMed  Google Scholar 

  • Bora E, Sehitoglu G, Aslier M, Atabay I, Veznedaroglu B. Theory of mind and unawareness of illness in schizophrenia: is poor insight a mentalizing deficit? Eur Arch Psychiatry Clin Neurosci. 2007;257:104–11.

    Article  PubMed  Google Scholar 

  • Boyer L, Aghababian V, Richieri R, et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:271–6.

    Article  CAS  PubMed  Google Scholar 

  • Boyer L, Lancon C, Baumstarck K, et al. Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial. Br J Psychiatry. 2013;202:447–53.

    Article  PubMed  Google Scholar 

  • Briand C, Vasiliadis HM, Lesage A, et al. Including integrated psychological treatment as part of standard medical therapy for patients with schizophrenia: clinical outcomes. J Nerv Ment Dis. 2006;194:463–70.

    Article  PubMed  Google Scholar 

  • Brissos S, Dias VV, Balanza-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129:133–6.

    Article  PubMed  Google Scholar 

  • Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:5372.

    Article  Google Scholar 

  • Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophr Res Treatment. 2012;2012:576369.

    Article  PubMed  PubMed Central  Google Scholar 

  • Carroll A, Fattah S, Clyde Z, et al. Correlates of insight and insight change in schizophrenia. Schizophr Res. 1999;35:247–53.

    Article  CAS  PubMed  Google Scholar 

  • Chang LR, Lin YH, Kuo TB, et al. Autonomic modulation and health-related quality of life among schizophrenic patients treated with non-intensive case management. PLoS One. 2013;6:e26378.

    Article  CAS  Google Scholar 

  • Chen EY, Tang JY, Hui CL, et al. Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Early Interv Psychiatry. 2011;5:315–23.

    Article  PubMed  Google Scholar 

  • Chou KR, Shih YW, Chang C, et al. Psychosocial rehabilitation activities, empowerment, and quality of community-based life for people with schizophrenia. Arch Psychiatr Nurs. 2012;26:285–94.

    Article  PubMed  Google Scholar 

  • Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17:567–76.

    Article  PubMed  Google Scholar 

  • Cohen CI, Pathak R, Ramirez PM, Vahia I. Outcome among community dwelling older adults with schizophrenia: results using five conceptual models. Community Ment Health J. 2009;45:151–6.

    Article  PubMed  Google Scholar 

  • Cohen CI, Hassamal SK, Begum N. General coping strategies and their impact on quality of life in older adults with schizophrenia. Schizophr Res. 2011;127:223–8.

    Article  PubMed  Google Scholar 

  • Cooke MA, Peters ER, Kuipers E, Kumari V. Disease, deficit or denial? Models of poor insight in psychosis. Acta Psychiatr Scand. 2005;112:4–17.

    Article  CAS  PubMed  Google Scholar 

  • Dan A, Kumar S, Avasthi A, Grover S. A comparative study on quality of life of patients of schizophrenia with and without depression. Psychiatry Res. 2011;189:185–9.

    Article  PubMed  Google Scholar 

  • de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125–8.

    Article  PubMed  Google Scholar 

  • DeHaan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale [Medico-economic study of Leponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. Psychopharmacology (Berl). 2002;162:24–8.

    Article  CAS  Google Scholar 

  • Delespaul PH. Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschr Psychiatr. 2013;55:427–38.

    PubMed  Google Scholar 

  • Dickerson FB, Boronow JJ, Ringel N, Parente F. Lack of insight among outpatients with schizophrenia. Psychiatr Serv (Washington, DC). 1997;48:195–9.

    Article  CAS  Google Scholar 

  • Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol. 2007;22:51–5.

    PubMed  Google Scholar 

  • Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res. 2003;62:165–73.

    Article  PubMed  Google Scholar 

  • Drake RJ, Pickles A, Bentall RP, et al. The evolution of insight, paranoia and depression during early schizophrenia. Psychol Med. 2004;34:285–92.

    Article  CAS  PubMed  Google Scholar 

  • Eack S, Newhill C. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225–37.

    Article  PubMed  PubMed Central  Google Scholar 

  • Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014a;68:416–27.

    Article  PubMed  Google Scholar 

  • Einarson TR, Pudas H, Goswami P, van Impe K, Bereza BG. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ. 2014b,68:1–29.

    Google Scholar 

  • Eklund M. Work status, daily activities and quality of life among people with severe mental illness. Qual Life Res. 2009;18:163–70.

    Article  PubMed  Google Scholar 

  • Faerden A, Nesvag R, Marder SR. Definitions of the term ‘recovered’ in schizophrenia and other disorders. Psychopathology. 2008;41:271–8.

    Article  PubMed  Google Scholar 

  • (FDA) USFaDA. Patient-reported outcome measures: use in medical product development to support labelling claims. In: Guidance for industry. FDA, US Government. 2006.

    Google Scholar 

  • Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69:514–9.

    Article  PubMed  Google Scholar 

  • Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012a;197:199–205.

    Article  PubMed  Google Scholar 

  • Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One. 2012b;7:e37087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L. Schizophrenia and quality of life: how important are symptoms and functioning? Int J Ment Heal Syst. 2010;4:31.

    Article  Google Scholar 

  • Gilleen J, David AS. The cognitive neuropsychiatry of delusions: from psychopathology to neuropsychology and back again. Psychol Med. 2005;35:5–12.

    Article  PubMed  Google Scholar 

  • Goldberg RW, Green-Paden LD, Lehman AF, Gold JM. Correlates of insight in serious mental illness. J Nerv Ment Dis. 2001;189:137–45.

    Article  CAS  PubMed  Google Scholar 

  • Green C, Garety PA, Freeman D, et al. Content and affect in persecutory delusions. Br J Clin Psychol Br Psychol Soc. 2006;45:561–77.

    Article  Google Scholar 

  • Haro JM, Novick D, Perrin E, Bertsch J, Knapp M. Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship? Psychiatry Res. 2014;220:163–9.

    Article  PubMed  Google Scholar 

  • Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35:300–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Harvey PD, Pappadopulos E, Lombardo I, Kremer CM. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. Schizophr Res. 2009;115:24–9.

    Article  PubMed  Google Scholar 

  • Harvey PD, Sabbag S, Prestia D, et al. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res. 2012;46:1546–52.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M. Insight into psychosis and quality of life. Compr Psychiatry. 2006;47:265–9.

    Article  PubMed  Google Scholar 

  • Hayhurst KP, Drake RJ, Massie JA, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2013;29:191–6.

    Article  PubMed  Google Scholar 

  • Haynes VS, Zhu B, Stauffer VL, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.

    Article  PubMed  PubMed Central  Google Scholar 

  • Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–98.

    Article  CAS  PubMed  Google Scholar 

  • Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93:160–8.

    Article  PubMed  Google Scholar 

  • Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932–9.

    Article  PubMed  Google Scholar 

  • Hofer A, Rettenbacher MA, Widschwendter CG, et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256(4):246–55.

    Article  PubMed  Google Scholar 

  • Hofer A, Rettenbacher MA, Edlinger M, et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. 2007;40:1–8.

    Article  CAS  PubMed  Google Scholar 

  • Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171–80.

    Article  CAS  PubMed  Google Scholar 

  • Iqbal Z, Birchwood M, Chadwick P, Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 2. Testing the validity of a social ranking model. Br J Psychiatry. 2000;177:522–8.

    Article  CAS  PubMed  Google Scholar 

  • Jaaskelainen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39:1296–306.

    Article  PubMed  Google Scholar 

  • Jaaskelainen E, Haapea M, Rautio N, et al. Twenty years of schizophrenia research in the Northern Finland Birth Cohort 1966: a systematic review. Schizophr Res Treatment. 2015;2015:524875.

    Article  PubMed  PubMed Central  Google Scholar 

  • Karadayi G, Emiroglu B, Ucok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychiatry. 2012;52:701–7.

    Article  Google Scholar 

  • Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38:320–6.

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75–80.

    Article  PubMed  Google Scholar 

  • Karow A, Pajonk FG, Reimer J, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2008;258:152–9.

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Moritz S, Lambert M, Schottle D, Naber D. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012a;27:401–5.

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Naber D, Lambert M, Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry. 2012b;27(6):426–31.

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Reimer J, Konig HH, et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012c;73:e402–8.

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Wittmann L, Schottle D, Schafer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2015;16:185–95.

    Google Scholar 

  • Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res. 2003;60:71–80.

    Article  PubMed  Google Scholar 

  • Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. In: Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrchet/Boston: Kluwer; 2003.

    Google Scholar 

  • Koren D, Seidman LJ, Poyurovsky M, et al. The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study. Schizophr Res. 2004;70:195–202.

    Article  PubMed  Google Scholar 

  • Kumazaki H, Kobayashi H, Niimura H, et al. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study. Compr Psychiatry. 2012;53:946–51.

    Article  PubMed  Google Scholar 

  • Kurtz MM, Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship? Schizophr Res. 2010;127:157–62.

    Article  Google Scholar 

  • Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690–7.

    Article  PubMed  Google Scholar 

  • Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007;115:106–13.

    Article  CAS  PubMed  Google Scholar 

  • Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220–9.

    Article  CAS  PubMed  Google Scholar 

  • Lambert M, Schimmelmann BG, Naber D, et al. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277–83.

    Article  CAS  PubMed  Google Scholar 

  • Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010a;12:393–407.

    PubMed  PubMed Central  Google Scholar 

  • Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010b;25(4):220–9.

    Article  CAS  PubMed  Google Scholar 

  • Lambert M, Bock T, Schottle D, et al. Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2010c;71(10):1313–23.

    Article  PubMed  Google Scholar 

  • Landolt K, Rossler W, Burns T, et al. The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2012a;262:207–16.

    Article  PubMed  Google Scholar 

  • Landolt K, Rossler W, Burns T, et al. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med. 2012b;42:1461–73.

    Article  CAS  PubMed  Google Scholar 

  • Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Winchester, England). 2006;10:iii–iv, ix–xi, 1–165.

    CAS  Google Scholar 

  • Liraud F, Droulout T, Parrot M, Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J Nerv Ment Dis. 2004;192:352–6.

    Article  PubMed  Google Scholar 

  • Maat A, Fett AK, Derks E. Social cognition and quality of life in schizophrenia. Schizophr Res. 2012;137:212–8.

    Article  PubMed  Google Scholar 

  • Marchinko S, Clarke D. The Wellness Planner: empowerment, quality of life, and continuity of care in mental illness. Arch Psychiatr Nurs. 2011;25:284–93.

    Article  PubMed  Google Scholar 

  • Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev Online. 2011;(4):CD001089.

    Google Scholar 

  • Maurino J, Sanjuan J, Haro JM, Diez T, Ballesteros J. Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence. 2011;5:471–4.

    Article  PubMed  PubMed Central  Google Scholar 

  • McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis. 1989;177:43–7.

    Article  CAS  PubMed  Google Scholar 

  • Meesters PD, Comijs HC, de Haan L, et al. Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res. 2011;147:275–80.

    Article  Google Scholar 

  • Meijer CJ, Koeter MW, Sprangers MA, Schene AH. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2009;44:361–8.

    Article  PubMed  Google Scholar 

  • Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36:1349–62.

    Article  CAS  PubMed  Google Scholar 

  • Mintz AR, Addington J, Addington D. Insight in early psychosis: a 1-year follow-up. Schizophr Res. 2004;67:213–7.

    Article  PubMed  Google Scholar 

  • Moritz S, Werner R, von Collani G. The inferiority complex in paranoia re-addressed. A study with the Implicit Association Test. Cogn Neuropsychiatry. 2006;11:402–15.

    Article  PubMed  Google Scholar 

  • Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10 Suppl 3:133–8.

    CAS  PubMed  Google Scholar 

  • Naber D, Kollack-Walker S, Chen J, et al. Predicting a ‘combined treatment outcome’ in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being. Pharmacopsychiatry. 2013;46:114–9.

    Article  CAS  PubMed  Google Scholar 

  • Nordentoft M, Ohlenschlaeger J, Thorup A, et al. Deinstitutionalization revisited: a 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. Psychol Med. 2010;40:1619–26.

    Article  CAS  PubMed  Google Scholar 

  • Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37 Suppl 2:S33–40.

    Article  PubMed  PubMed Central  Google Scholar 

  • O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–70.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ojeda N, Sanchez P, Pena J, et al. An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms. Actas Esp Psiquiatr. 2012;40:10–8.

    PubMed  Google Scholar 

  • Pedrelli P, McQuaid JR, Granholm E, et al. Measuring cognitive insight in middle-aged and older patients with psychotic disorders. Schizophr Res. 2004;71:297–305.

    Article  PubMed  Google Scholar 

  • Penn DL, Uzenoff SR, Perkins D, et al. A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis. Schizophr Res. 2011;125:247–56.

    Article  PubMed  PubMed Central  Google Scholar 

  • Peuskens J, Gorwood P. How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur Psychiatry. 2012;27:391–5.

    Article  CAS  PubMed  Google Scholar 

  • Pitkanen A, Valimaki M, Kuosmanen L, et al. Patient education methods to support quality of life and functional ability among patients with schizophrenia: a randomised clinical trial. Qual Life Res. 2012;21:247–56.

    Article  PubMed  Google Scholar 

  • Priebe S, McCabe R, Junghan U, et al. Association between symptoms and quality of life in patients with schizophrenia: a pooled analysis of changes over time. Schizophr Res. 2011;133:17–21.

    Article  PubMed  Google Scholar 

  • Putzhammer A, Perfahl M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry. 2005;38:132–8.

    Article  CAS  PubMed  Google Scholar 

  • Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147–50.

    Article  PubMed  Google Scholar 

  • Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150:339–42.

    Article  PubMed  Google Scholar 

  • Rajagopalan K, Hassan M, O’Day K, Meyer K, Grossman F. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. J Med Econ. 2013;16:951–61.

    Article  PubMed  Google Scholar 

  • Reichenberg A, Caspi A, Harrington H, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry. 2010;167:160–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Renwick L, Jackson D, Foley S, et al. Depression and quality of life in first-episode psychosis. Compr Psychiatry. 2012;53:451–5.

    Article  PubMed  Google Scholar 

  • Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis. 2003;191:287–94.

    PubMed  Google Scholar 

  • Ritsner MS, Grinshpoon A. Ten-year quality of life outcomes of patients with schizophrenia and schizoaffective disorders. Clin Schizophr Relat Psychoses. 2015, Fall issue, 125–134.

    Google Scholar 

  • Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14:1693–703.

    Article  PubMed  Google Scholar 

  • Ritsner MS, Lisker A, Arbitman M. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2014;21:837–47.

    Article  Google Scholar 

  • Rocca P, Giugiario M, Montemagni C, et al. Quality of life and psychopathology during the course of schizophrenia. Compr Psychiatry. 2009;50:542–8.

    Article  PubMed  Google Scholar 

  • Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.

    Article  CAS  PubMed  Google Scholar 

  • Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry. 2000;177:149–55.

    Article  CAS  PubMed  Google Scholar 

  • Sanz M, Constable G, Lopez-Ibor I, Kemp R, David AS. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med. 1998;28:437–46.

    Article  CAS  PubMed  Google Scholar 

  • Schennach-Wolff R, Jager M, Seemuller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113:210–7.

    Article  PubMed  Google Scholar 

  • Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol. 2005;15:249–58.

    Article  PubMed  Google Scholar 

  • Schöttle D, Karow A, Schimmelmann BG, Lambert M. Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry. 2013;26:384–408.

    Article  PubMed  Google Scholar 

  • Schroeder K, Huber CG, Jelinek L, Moritz S. Subjective well-being, but not subjective mental functioning shows positive associations with neuropsychological performance in schizophrenia-spectrum disorders. Compr Psychiatry. 2012;54:824–30.

    Article  Google Scholar 

  • Schwartz RC. Insight and illness in chronic schizophrenia. Compr Psychiatry. 1998;39:249–54.

    Article  CAS  PubMed  Google Scholar 

  • Schwartz RC, Smith SD. Suicidality and psychosis: the predictive potential of symptomatology and insight into illness. J Psychiatr Res. 2004;38:185–91.

    Article  PubMed  Google Scholar 

  • Sim K, Mahendran R, Siris SG, Heckers S, Chong SA. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res. 2004;129:141–7.

    Article  PubMed  Google Scholar 

  • Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004;38:169–76.

    Article  PubMed  Google Scholar 

  • Stein LI, Santos AB. Assertive community treatment of persons with severe mental illness. New York: W. W. Norton & Company, Inc; 2000.

    Google Scholar 

  • Subotnik KL, Nuechterlein KH, Irzhevsky V, et al. Is unawareness of psychotic disorder a neurocognitive or psychological defensiveness problem? Schizophr Res. 2005;75:147–57.

    Article  PubMed  Google Scholar 

  • Sugawara N, Yasui-Furukori N, Sato Y, et al. Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry. 2013;13:108.

    Article  PubMed  PubMed Central  Google Scholar 

  • Switaj P, Wciorka J, Smolarska-Switaj J, Grygiel P. Extent and predictors of stigma experienced by patients with schizophrenia. Eur Psychiatry. 2009;24:513–20.

    Article  CAS  PubMed  Google Scholar 

  • Tang IC, Wu HC. Quality of life and self-stigma in individuals with schizophrenia. Psychiatry Q. 2012;83:497–507.

    Article  Google Scholar 

  • Teague GB, Mueser KT, Rapp CA. Advances in fidelity measurement for mental health services research: four measures. Psychiatr Serv (Washington, DC). 2012;63:765–71.

    Article  Google Scholar 

  • Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304–15.

    Article  PubMed  Google Scholar 

  • Ucok A, Karadayi G, Emiroglu B, Sartorius N. Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. Psychiatry Res. 2013;209:333–9.

    Article  PubMed  Google Scholar 

  • Urbach M, Brunet-Gouet E, Bazin N, Hardy-Bayle MC, Passerieux C. Correlations of theory of mind deficits with clinical patterns and quality of life in schizophrenia. Front Psychiatry. 2013;4:30.

    Article  PubMed  PubMed Central  Google Scholar 

  • van Baars AW, Wierdsma AI, Hengeveld MW, Mulder CL. Improved insight affects social outcomes in involuntarily committed psychotic patients: a longitudinal study in the Netherlands. Compr Psychiatry. 2013;54:873–9.

    Article  PubMed  Google Scholar 

  • Vancampfort D, Vansteelandt K, Scheewe T, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012a;126:12–20.

    Article  CAS  PubMed  Google Scholar 

  • Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012b;125:352–62.

    Article  CAS  PubMed  Google Scholar 

  • Vatne S, Bjorkly S. Empirical evidence for using subjective quality of life as an outcome variable in clinical studies A meta-analysis of correlates and predictors in persons with a major mental disorder living in the community. Clin Psychol Rev. 2008;28:869–89.

    Article  PubMed  Google Scholar 

  • Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1–46; quiz 47–8.

    PubMed  Google Scholar 

  • Ware J. SF-36 health survey. Manual and interpretation guide. Boston: Health Institute, New England Medical Center; 1993.

    Google Scholar 

  • Whitty P, Browne S, Clarke M, et al. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. J Nerv Ment Dis. 2004;192:805–9.

    Article  PubMed  Google Scholar 

  • WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28:551–8.

    Article  Google Scholar 

  • Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull. 2007;33:792–6.

    Article  PubMed  Google Scholar 

  • Yeh CB, Huang YS, Tang CS, et al. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nord J Psychiatry. 2013;68:219–24.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy & Department of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Anne Karow MD & Martin Lambert MD

  2. Institute for Medical Psychology, Centre for Psychosocial Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

    Monika Bullinger PhD

Authors
  1. Anne Karow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monika Bullinger PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Lambert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Karow MD .

Editor information

Editors and Affiliations

  1. Psychiatry, University of Toronto, Toronto, Ontario, Canada

    A. George Awad

  2. Department of Psychiatry, University of Western Ontario, London, Ontario, Canada

    Lakshmi N.P. Voruganti

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Karow, A., Bullinger, M., Lambert, M. (2016). Quality of Life as an Outcome and a Mediator of Other Outcomes in Patients with Schizophrenia. In: Awad, A., Voruganti, L. (eds) Beyond Assessment of Quality of Life in Schizophrenia. Adis, Cham. https://doi.org/10.1007/978-3-319-30061-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30061-0_9

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-30059-7

  • Online ISBN: 978-3-319-30061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation